[Broncaspin in respiratory diseases in pediatrics. Clinical contribution].
Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect. The preparation was outstanding for speed of action, local and general tolerance, and the absence of haematological, hepatic or renal side-effects. The new drug is considered to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.
D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy; D004417:Dyspnea / Q000188:drug therapy; D005334:Fever / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007827:Laryngitis / Q000188:drug therapy; D010612:Pharyngitis / Q000188:drug therapy; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D014136:Tracheitis / Q000188:drug therapy
D001241:Aspirin; C023557:guacetisal
Il Broncaspin nelle affezioni respiratorie in pediatria. Contributo clinico.